Paper32205232
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).
Runfeng L and 17 others. Pharmacol Res, 2020. Cited by 478 papers, by iCite.
Cite this record
ConductScience Library. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Papers, record 32205232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32205232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents | Major topic |
| Antiviral Agents | Major topic |
| Betacoronavirus | Major topic |
| Drugs, Chinese Herbal | Major topic |
| Animals | |
| Cell Line | |
| Chlorocebus aethiops | |
| Microscopy, Electrochemical, Scanning | |
| SARS-CoV-2 |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04380870 | Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19 | Background |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 34802883 | Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]. | https://conductscience.org/library/papers/34802883 | PubMed |
| Comment in | 33197600 | Letter to the Editor in response to the articles 'Lianhuaqingwen exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2)' and 'Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.' | https://conductscience.org/library/papers/33197600 | PubMed |
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32015507 | A pneumonia outbreak associated with a new coronavirus of probable bat origin. | Nature | 2020 | https://conductscience.org/library/papers/32015507 | PubMed |
| 2 | 16830000 | Clinical and laboratory findings of SARS in Singapore. | Ann Acad Med Singap | 2006 | https://conductscience.org/library/papers/16830000 | PubMed |
| 3 | 32020029 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. | Cell Res | 2020 | https://conductscience.org/library/papers/32020029 | PubMed |
| 4 | 26868298 | Coronaviruses - drug discovery and therapeutic options. | Nat Rev Drug Discov | 2016 | https://conductscience.org/library/papers/26868298 | PubMed |
| 5 | 31996494 | Drug treatment options for the 2019-new coronavirus (2019-nCoV). | Biosci Trends | 2020 | https://conductscience.org/library/papers/31996494 | PubMed |
| 6 | 32145402 | Traditional Chinese medicine for COVID-19 treatment. | Pharmacol Res | 2020 | https://conductscience.org/library/papers/32145402 | PubMed |
| 7 | 31992388 | Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. | Euro Surveill | 2020 | https://conductscience.org/library/papers/31992388 | PubMed |
| 8 | 31988464 | China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. | Nat Med | 2020 | https://conductscience.org/library/papers/31988464 | PubMed |
| 9 | 23891402 | Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. | Lancet Infect Dis | 2013 | https://conductscience.org/library/papers/23891402 | PubMed |
| 10 | 31774950 | A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31774950 | PubMed |
| 11 | 32031570 | Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. | JAMA | 2020 | https://conductscience.org/library/papers/32031570 | PubMed |
| 12 | 31986264 | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. | Lancet | 2020 | https://conductscience.org/library/papers/31986264 | PubMed |
| 13 | 32004066 | Novel Wuhan (2019-nCoV) Coronavirus. | Am J Respir Crit Care Med | 2020 | https://conductscience.org/library/papers/32004066 | PubMed |
| 14 | 31988490 | Outbreak of a novel coronavirus. | Nat Rev Microbiol | 2020 | https://conductscience.org/library/papers/31988490 | PubMed |
| 15 | 31226023 | Human Coronavirus: Host-Pathogen Interaction. | Annu Rev Microbiol | 2019 | https://conductscience.org/library/papers/31226023 | PubMed |
| 16 | 28085062 | Radix isatidis Polysaccharides Inhibit Influenza a Virus and Influenza A Virus-Induced Inflammation via Suppression of Host TLR3 Signaling In Vitro. | Molecules | 2017 | https://conductscience.org/library/papers/28085062 | PubMed |
| 17 | 22040504 | Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. | Chin Med J (Engl) | 2011 | https://conductscience.org/library/papers/22040504 | PubMed |
| 18 | 28235408 | The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. | BMC Complement Altern Med | 2017 | https://conductscience.org/library/papers/28235408 | PubMed |
Cited by388
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 478 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42947434 | Efficacy and safety of Lianhua Qingwen versus oseltamivir in children with influenza: a multicenter, randomized, double-blind, positive parallel-controlled study. | Pharm Biol | 2026 | https://conductscience.org/library/papers/42947434 | PubMed |
| 42568511 | Comparison of volatile organic compounds in different parts of Houttuynia cordata Thunb. via E-nose, GC-IMS, and multivariate statistical analysis. | Front Nutr | 2026 | https://conductscience.org/library/papers/42568511 | PubMed |
| 42549048 | The Redesign of the Molecular Scaffold of Viral Ion Channel Blockers. | Comput Struct Biotechnol J | 2026 | https://conductscience.org/library/papers/42549048 | PubMed |
| 42527947 | Forsythoside A alleviates experimental autoimmune encephalomyelitis by targeting Tnfaip2. | Chin Med | 2026 | https://conductscience.org/library/papers/42527947 | PubMed |
| 42504256 | Integrating the Wei-Qi-Ying-Blood Theory with Modern Pathophysiology: A Multitarget Translational Framework for Dengue Management. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42504256 | PubMed |
| 42475393 | Quercetin, a flavonoid, suppresses viral proliferation by interfering with the ubiquitin transfer from E1 to E2 enzymes. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42475393 | PubMed |
| 42453521 | Jing-Si Herbal Tea as a multitargeted complementary therapy: Evidence from preclinical and clinical studies. | Tzu Chi Med J | 2026 | https://conductscience.org/library/papers/42453521 | PubMed |
| 42370951 | Cloning and functional verification of genes LjHD8 and LjMIXTA1 related to trichome development in Lonicera japonica Thunb. | Planta | 2026 | https://conductscience.org/library/papers/42370951 | PubMed |
| 41971577 | Integrated network pharmacology, transcriptomics and experimental validation to explore mechanisms of Wenyang Jiedu Granule on IAV-induced pneumonia. | Chin Herb Med | 2026 | https://conductscience.org/library/papers/41971577 | PubMed |
| 41924162 | Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/41924162 | PubMed |
| 41909248 | Traditional Chinese medicine in influenza treatment: a bibliometric analysis integrating multiple databases. | Front Microbiol | 2026 | https://conductscience.org/library/papers/41909248 | PubMed |
| 41766236 | Effects of Traditional Chinese Medicine on Restoroing the immune balance of mild-to-moderate Patients with new coronavirus. | Indian J Pharmacol | 2026 | https://conductscience.org/library/papers/41766236 | PubMed |
| 41165505 | Molecular Roadmap of COVID-19: From Viral Entry to Therapeutic Targets. | Chem Biodivers | 2026 | https://conductscience.org/library/papers/41165505 | PubMed |
| 40872800 | Screening of Medicinal Herbs Identifies Cimicifuga foetida and Its Bioactive Component Caffeic Acid as SARS-CoV-2 Entry Inhibitors. | Viruses | 2025 | https://conductscience.org/library/papers/40872800 | PubMed |
| 40792265 | Mathematical modelling of the heterogeneity of disease progression and treatment outcomes in patients with COVID-19. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40792265 | PubMed |
| 40746319 | Identification, functional analysis, and clinical applications of defective viral genomes. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40746319 | PubMed |
| 40078906 | Role of innate immunity in SARS-CoV-2 infection. | Biosaf Health | 2023 | https://conductscience.org/library/papers/40078906 | PubMed |
| 40070503 | Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID-19 and facial neuritis. | World J Otorhinolaryngol Head Neck Surg | 2025 | https://conductscience.org/library/papers/40070503 | PubMed |
| 39946361 | Effect of Chinese herbal medicine (CHM) as an adjunctive therapy in distinct stages of patients with COVID-19: A systematic review and meta-analysis. | PLoS One | 2025 | https://conductscience.org/library/papers/39946361 | PubMed |
| 39897928 | SARS-CoV-2 drug resistance and therapeutic approaches. | Heliyon | 2025 | https://conductscience.org/library/papers/39897928 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCL2 | 6347 | PubTator's text mining | https://conductscience.org/library/genes/6347 | NCBI Gene |
| CCL3 | 6348 | PubTator's text mining | https://conductscience.org/library/genes/6348 | NCBI Gene |
| CXCL10 | 3627 | PubTator's text mining | https://conductscience.org/library/genes/3627 | NCBI Gene |
| GAPDH | 2597 | PubTator's text mining | https://conductscience.org/library/genes/2597 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL12B | 3593 | PubTator's text mining | https://conductscience.org/library/genes/3593 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32205232
GET https://conductscience.org/api/papers/v1/32205232/cited_by?page=2